First City Capital Management Inc. bought a new position in shares of Danaher Co. (NYSE:DHR – Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 760 shares of the conglomerate’s stock, valued at approximately $211,000.
Other hedge funds also recently bought and sold shares of the company. CarsonAllaria Wealth Management Ltd. acquired a new stake in shares of Danaher in the 2nd quarter valued at approximately $25,000. nVerses Capital LLC bought a new position in shares of Danaher during the second quarter worth about $25,000. MidAtlantic Capital Management Inc. acquired a new stake in Danaher in the 3rd quarter valued at approximately $40,000. MFA Wealth Advisors LLC acquired a new position in Danaher during the 2nd quarter worth approximately $51,000. Finally, Financial Connections Group Inc. bought a new position in shares of Danaher during the 2nd quarter worth approximately $51,000. 79.05% of the stock is currently owned by institutional investors.
Insider Transactions at Danaher
In related news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. This trade represents a 18.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.90% of the stock is currently owned by company insiders.
Danaher Stock Performance
Danaher (NYSE:DHR – Get Free Report) last issued its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same quarter in the previous year, the firm earned $2.02 earnings per share. The business’s revenue was up 3.1% compared to the same quarter last year. Sell-side analysts anticipate that Danaher Co. will post 7.51 EPS for the current year.
Danaher Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.47%. The ex-dividend date of this dividend was Friday, September 27th. Danaher’s dividend payout ratio (DPR) is 20.61%.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently issued reports on the stock. Wolfe Research upgraded shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 target price for the company in a research note on Thursday, October 31st. KeyCorp raised their target price on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. The Goldman Sachs Group increased their price target on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research note on Monday. Finally, Stephens reiterated an “overweight” rating and issued a $315.00 price target on shares of Danaher in a research report on Wednesday, October 23rd. Six equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and a consensus price target of $287.16.
Check Out Our Latest Report on Danaher
Danaher Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Read More
- Five stocks we like better than Danaher
- Profitably Trade Stocks at 52-Week Highs
- 3 High Flying Stocks That Could Stock Split in 2025
- 3 Healthcare Dividend Stocks to Buy
- Retail Sector Comeback Plays: SPDR S&P Retail ETF, FND, and SHAK
- What is the S&P/TSX Index?
- Top IoT Stocks: Why Samsara and Digi Are Thriving in 2025
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.